Intelligence / Healthtech / New Clinical Trials / Huabo Biopharm Co., Ltd.
Huabo Biopharm Co., Ltd.
6 Nov 2026: Trial registered · A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 6 Nov 2026
- Title
- A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose
- Conditions
- Psoriasis, Ankylosing Spondylitis
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- China
- Country
- China
- Reference
- NCT07920861
- Location
- China
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Huabo Biopharm Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from China
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.